Sublingual tirzepatide
A needle-free compounded form of the dual-incretin tirzepatide, absorbed under the tongue. The newest of the alternative forms — appealing for needle-averse patients, with the least published evidence.
| Generic name | tirzepatide (compounded sublingual) |
|---|---|
| Drug class | Dual GIP/GLP-1 receptor agonist (compounded form) |
| Form & route | Rapid-dissolve tablet (RDT) held under the tongue, typically once weekly |
| Typical dosing | Compounded protocols commonly run 3–7 mg weekly, with the highest steps reserved for provider-only escalation. Sublingual doses are NOT interchangeable with injection doses. |
| FDA status | Not FDA-approved. Compounded formulation available by prescription from licensed compounding pharmacies. |
What sublingual tirzepatide is Sublingual tirzepatide packages the dual GIP/GLP-1 agonist into a rapid-dissolve tablet (RDT) absorbed under the tongue. It is the needle-free counterpart to compounded tirzepatide injections, and the same caveats apply as for sublingual semaglutide — only more so, because tirzepatide is the newer molecule: - Not FDA-approved. No sublingual tirzepatide product has been through FDA review. There is no swallowed-tablet equivalent either (unlike semaglutide’s Rybelsus). - Not dose-equivalent to injections. Oral-mucosa absorption is lower and more variable than subcutaneous injection. Sublingual ladders (commonly 3 → 4 → 5 → 7 mg weekly in compounded protocols) cannot be mapped 1:1 onto Zepbound’s 2.5–15 mg injection ladder. - Evidence is the thinnest in the GLP-1 space. No randomized trials; support is pharmacokinetic reasoning and prescriber-reported experience. ## Why people choose it anyway The honest case: SURMOUNT-level results require taking the medication for a year or longer, and a meaningful fraction of people simply will not inject themselves weekly for that long. For a needle-averse patient choosing between no GLP-1 and a sublingual form with weaker evidence, the sublingual route can still be the better real-world decision — made with eyes open, with weight and side effects tracked, and with a switch to injections on the table if results stall. ## Practical notes - Tablets dissolve under the tongue over several minutes; food and drink are typically held briefly afterward to maximize absorption. - Compounded protocols usually cap self-directed escalation and reserve the top step for explicit provider sign-off. - The few telehealth programs offering sublingual tirzepatide are the ones with broad compounded-product menus — NexLife, for example, offers tirzepatide RDTs with the top step gated behind provider sign-off; vet any program against the checklist on where to get GLP-1s.
This is general information, not medical advice. Prescribing decisions belong with a licensed clinician who knows your history. Never buy GLP-1 medications from unverified sources.